Soligenix Inc Stock Price and Quote (2024)

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.84	Insider Own	0.23%	Shs Outstand	0.99M	Perf Week	25.82%
Market Cap	4.20M	Forward P/E	-	EPS next Y	-7.20	Insider Trans	0.00%	Shs Float	0.99M	Perf Month	-32.50%
Income	-7.01M	PEG	-	EPS next Q	-1.77	Inst Own	1.51%	Short Float	1.43%	Perf Quarter	-57.33%
Sales	0.00M	P/S	-	EPS this Y	43.04%	Inst Trans	-	Short Ratio	0.08	Perf Half Y	-54.33%
Book/sh	1.17	P/B	3.63	EPS next Y	0.00%	ROA	-73.17%	Short Interest	0.01M	Perf Year	-61.59%
Cash/sh	7.16	P/C	0.59	EPS next 5Y	1.00%	ROE	-23783.30%	52W Range	3.30 - 32.00	Perf YTD	-65.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	39.94%	ROI	-827.14%	52W High	-86.75%	Beta	1.91
Dividend TTM	-	Quick Ratio	1.07	Sales past 5Y	78.49%	Gross Margin	-232.18%	52W Low	28.48%	ATR (14)	0.62
Dividend Ex-Date	-	Current Ratio	1.07	EPS Y/Y TTM	79.70%	Oper. Margin	0.00%	RSI (14)	39.08	Volatility	19.68% 13.06%
Employees	15	Debt/Eq	4.16	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	48.00
Option/Short	No / Yes	LT Debt/Eq	0.10	EPS Q/Q	49.28%	Payout	-	Rel Volume	0.47	Prev Close	3.82
Sales Surprise	-50.00%	EPS Surprise	5.26%	Sales Q/Q	-	Earnings	May 10 BMO	Avg Volume	185.86K	Price	4.24
SMA20	-13.03%	SMA50	-28.73%	SMA200	-51.36%	Trades		Volume	87,511	Change	10.99%

open in yahoo|&nbspopen in reuters|&nbspopen in marketwatch|&nbspopen in google|&nbspopen in EDGAR

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-20	Downgrade	Dawson James	Buy → Neutral
Jan-31-18	Downgrade	H.C. Wainwright	Buy → Neutral	$5.50 → $2.70
Aug-14-17	Reiterated	Maxim Group	Buy	$4 → $5
Jul-17-17	Initiated	H.C. Wainwright	Buy	$11

Jun-14-24 07:30AM	A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference (PR Newswire)
Jun-07-24 09:00AM	Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) -8.92%
Jun-05-24 08:00AM	Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte Replication Trial (GlobeNewswire)
May-31-24 07:30AM	Soligenix Announces Reverse Stock Split (PR Newswire) -10.00%
May-29-24 07:30AM	Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting (PR Newswire)
07:30AM	Loading…
May-24-24 07:30AM	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire)
May-23-24 07:30AM	Soligenix Encourages Stockholders to Vote 'FOR' Reverse Stock Split (PR Newswire) -8.65%
May-21-24 12:35PM	PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon (GlobeNewswire)
07:30AM	SuVax and MarVax Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference (PR Newswire)
May-20-24 07:30AM	Soligenix Encourages Stockholders to Vote Prior to Annual Meeting (PR Newswire)
May-16-24 07:30AM	Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice (PR Newswire) +7.29%
May-13-24 10:54AM	SNGX Stock Earnings: Soligenix Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-10-24 07:30AM	Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results (PR Newswire)
May-06-24 07:30AM	Soligenix to Present at Upcoming Conferences (PR Newswire)
Apr-25-24 07:30AM	Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa (PR Newswire) +11.49%
08:30AM	Loading…
Apr-18-24 08:30AM	Soligenix Announces Pricing of $4.75 Million Public Offering (PR Newswire) -14.65%
Apr-15-24 03:55PM	Why Is Penny Stock Soligenix Trading Higher On Monday? (Benzinga) +21.73%
11:18AM	Why Is Soligenix (SNGX) Stock Up 58% Today? (InvestorPlace)
07:30AM	FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection (PR Newswire)
Apr-11-24 07:30AM	FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection (PR Newswire) -16.05%
Apr-03-24 07:30AM	Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte With the European Medicines Agency (PR Newswire) -10.15%
Mar-15-24 01:53PM	SNGX Stock Earnings: Soligenix Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:30AM	Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results (PR Newswire)
Feb-08-24 07:30AM	Soligenix Announces Formation of Behet's Disease Medical Advisory Board (PR Newswire) +5.54%
Jan-26-24 09:00AM	Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jan-25-24 07:30AM	Soligenix to Present at The Microcap Conference (PR Newswire)
Jan-08-24 07:30AM	FDA Grants Soligenix 'Fast Track' Designation for Dusquetide in the Treatment of Oral Lesions of Behet's Disease (PR Newswire) +16.68%
Jan-04-24 07:30AM	Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis (PR Newswire)
Jan-02-24 07:30AM	Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses (PR Newswire) +12.26%
Dec-01-23 07:30AM	'HyBryte Use in Early-Stage Cutaneous T-Cell Lymphoma' Published in Frontiers in Drug Discovery (PR Newswire) -25.53%
11:07AM	Loading…
Nov-30-23 11:07AM	Why Is Soligenix (SNGX) Stock Up 285% Today? (InvestorPlace) +135.97%
07:30AM	Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behet's Disease (PR Newswire)
Nov-17-23 04:00PM	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire) +7.61%
Nov-13-23 08:12AM	Soligenix Q3 Loss Narrows (RTT News)
07:30AM	Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results (PR Newswire)
Oct-20-23 04:00PM	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire)
09:00AM	ASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Oct-16-23 07:30AM	Soligenix to Present at The ThinkEquity Conference (PR Newswire)
Oct-13-23 09:00AM	SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Oct-06-23 09:00AM	Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Sep-25-23 07:30AM	Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures (PR Newswire)
Sep-22-23 04:00PM	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders (PR Newswire) +5.58%
Aug-24-23 05:30AM	SNGX: HyBryte Expanded Treatment Trial Underway (Zacks)
Aug-21-23 07:30AM	Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results (PR Newswire)
Aug-11-23 10:05AM	BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV (ACCESSWIRE)
Aug-10-23 07:30AM	HyBryte Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment (PR Newswire)
Jul-19-23 07:13AM	SNGX: Expanding SGX302 Phase 2a Study in Psoriasis (Zacks)
Jul-11-23 07:30AM	Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis (PR Newswire)
Jun-29-23 08:07AM	Soligenix, Inc. CEO is Featured in an Interview with SmallCaps Daily (NewMediaWire)
Jun-02-23 09:00AM	Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R) (ACCESSWIRE)
May-30-23 05:00AM	SNGX: Positive Results for Compatibility Study of HyBryte in CTCL (Zacks Small Cap Research)
May-16-23 07:30AM	Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis (PR Newswire) -6.02%
May-15-23 07:30AM	Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results (PR Newswire) +6.85%
May-11-23 07:30AM	Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire) -5.68%
May-09-23 04:05PM	Soligenix Announces Closing of $8.5 Million Public Offering (PR Newswire) -12.57% -10.22%
May-05-23 09:05AM	Soligenix Announces Pricing of $8.5 Million Public Offering (PR Newswire) -51.75%
May-04-23 03:54PM	Why Are Soligenix Shares Trading Higher Today (Benzinga) +60.56%
07:30AM	Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
May-03-23 07:30AM	Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors (PR Newswire) -11.26%
May-01-23 07:30AM	Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease (PR Newswire) +9.74%
Apr-24-23 09:18AM	SNGX: Planning for Second Phase 3 Study for HyBryte in CTCL (Zacks Small Cap Research)
07:30AM	Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
Apr-14-23 01:39PM	FDA Asks For Additional Successful Trial To Approve Soligenix's Rare Cancer Candidate (Benzinga)
07:30AM	Soligenix Provides Regulatory Update on HyBryte (PR Newswire)
Apr-05-23 07:30AM	Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte and SGX302 (PR Newswire)
Apr-03-23 11:11AM	SNGX: Meeting with FDA to Discuss Refusal to File Letter (Zacks Small Cap Research)
07:30AM	Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
Mar-31-23 07:30AM	Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results (PR Newswire)
Mar-09-23 07:30AM	Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire) +6.62%
Feb-16-23 11:54AM	Soligenix, Inc: Vital Vaccine Development Program has Potential to Address Future Marburg Virus Outbreaks (NewMediaWire)
Feb-14-23 09:55AM	Why Are Soligenix Shares Plummeting Today? (Benzinga) -18.10%
07:59AM	UPDATE 1-U.S. FDA declines to review Soligenix's cancer drug (Reuters)
07:30AM	Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
Feb-09-23 07:30AM	Soligenix Announces Reverse Stock Split (PR Newswire) -13.02%
Jan-19-23 07:30AM	Soligenix Invited to Present at the Virtual Investor Summit Event (PR Newswire)
Jan-12-23 08:30AM	Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024 (NewMediaWire)
Jan-09-23 05:36AM	SNGX: Seeking Potential Reverse Stock Split (Zacks Small Cap Research)
Dec-23-22 04:01PM	Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock (PR Newswire) -22.52%
Dec-20-22 08:30AM	Soligenix Delivers Two Pivotal Milestones (NewMediaWire)
07:30AM	Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge (PR Newswire)
Dec-19-22 07:30AM	Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis (PR Newswire)
Dec-16-22 12:09PM	7 Stocks to Add to Your 10x Watchlist (InvestorPlace)
05:52AM	SNGX: HyBryte NDA Submitted (Zacks Small Cap Research)
Dec-15-22 07:30AM	Soligenix Announces Submission of New Drug Application to the FDA for HyBryte in the Treatment of Cutaneous T-cell Lymphoma (PR Newswire) +13.48%
Dec-06-22 08:30AM	Soligenix Positioned for Growth: Late-stage Pipeline and Key Q4 Milestones (NewMediaWire) -5.43%
Nov-16-22 10:28AM	UPDATE: Soligenix, Inc. to Showcase 2022 Milestones in Business Update Fireside Chat with PCG Advisory (NewMediaWire)
07:00AM	Soligenix, Inc. to Showcase 2022 Milestones in Business Update Fireside Chat With PCG Advisory (NewMediaWire)
Nov-15-22 07:30AM	Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program (PR Newswire) -6.80%
Nov-14-22 05:39AM	SNGX: HyBryte NDA to be Submitted Before the End of 2022 (Zacks Small Cap Research)
Nov-13-22 07:12AM	Soligenix Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-11-22 09:30AM	Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference (Newsfile)
Nov-10-22 07:30AM	Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results (PR Newswire)
Nov-07-22 09:30AM	New to The Street Announces Five Corporate Interviews on Episode #404, Airing on the Fox Business Network, Tonight, Monday, November 7, 2022, at 10:30 PM PT (GlobeNewswire)
Oct-28-22 06:45AM	SNGX: Invited to Submit BARDA Contract Proposal for Filovirus Vaccines (Zacks Small Cap Research)
Oct-27-22 07:30AM	Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses (PR Newswire)
Oct-25-22 07:30AM	Soligenix Announces Formation of Psoriasis Medical Advisory Board (PR Newswire)
Oct-24-22 09:30AM	New to The Street TV Announces its 399th Show, Featuring Five Corporate Interviews, Airing on the Fox Business Network, Tonight, Monday, October 24, 2022, at 10:30 PM PT (GlobeNewswire) +8.09%
Oct-21-22 09:30AM	New to The Street / Newsmax TV Announces its Nine Corporate Interviews for This Week's TV Broadcast, Episode #398, October 23, 2022, 10-11 AM ET (GlobeNewswire)
Oct-20-22 08:30AM	Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting (PR Newswire)
Oct-17-22 10:16AM	UPDATE: New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets (GlobeNewswire) +5.44%

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions withourpremium features. Real-time quotes, advancedvisualizations, backtesting, and much more.

Learn more about FINVIZ*Elite